Chemomab Therapeutics Ltd. Sponsored ADR CMMB 深 滬
已收盤 12-24 16:00:00 美东时间
1.88
-0.020
-1.05%
華盛通- 最 高2.0502
- 今 開2.0502
- 成交量 10.23万股
- 最 低 1.79
- 昨 收 1.90
- 總市值 3903.69万
- 52周最高 9.84
- 市盈率 靜 --
- 換手率 0.49%
- 52周最低 1.73
- 委 比 14.23%
- 總股本 2076.43万
- 歷史最高 736.00
- 量 比 0.95
- 振 幅 13.69%
- 歷史最低 1.68
- 每 手 1
- 風險率 1.84%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Chemomab Therapeutics Data From Phase 2 SPRING Study Shows Nebokitug Was Safe, Well Tolerated In Participants With Primary Sclerosing Cholangitis At Up To 48 Weeks Of Treatment
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the results of
12-02 21:16
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Chemomab Therapeutics Ltd. announced that its co-founder and CEO, Dr. Adi Mor, will present at Oppenheimer's Movers in Rare Disease Summit on December 11, 2025, in New York City. Dr. Mor will provide a corporate overview and hold one-on-one meetings with attendees. Chemomab is a biotech company developing innovative therapeutics for fibro-inflammatory diseases, particularly focusing on nebokitug, a first-in-class monoclonal antibody targeting CCL...
11-24 13:00
Chemomab Therapeutics Advances PSC Treatment with Phase 3 Trial
Chemomab Therapeutics Ltd. ( ($CMMB) ) has released its Q3 earnings. Here is a ...
11-22 11:53
Chemomab Therapeutics GAAP EPS of $0.00
Chemomab Therapeutics press release (CMMB): Q3 GAAP EPS of $0.00. Net loss was $1.7 million, or a net loss of less than one-half of one cent per basic and diluted ordinary share for the third quarter ...
11-20 21:33
Chemomab Therapeutics Q3 EPS $(0.28) Beats $(0.40) Estimate
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.40) by 30 percent. This is a 65 percent increase over losses of $(0.80) per share from
11-20 21:30
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Therapeutics Ltd announced positive updates on its nebokitug Phase 3 trial design for primary sclerosing cholangitis (PSC), receiving support from both the FDA and EMA for a single registration trial using a clinical event composite endpoint. Data from the Phase 2 SPRING trial's open-label extension (OLE) showed favorable safety and consistent improvements in key biomarkers, further reinforcing nebokitug's disease-modifying potential. Th...
11-20 13:00
Chemomab To Present Abstracts Highlighting New Clinical Data From Nebokitug Phase 2 SPRING Trial In Primary Sclerosing Cholangitis, At AASLD 2025
— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks——New Clinical Data Provides Insights on
11-06 21:09
Silkwave Inc. Announces Changes in Company Secretary Position
CMMB Vision Holdings ( ($HK:0471) ) has issued an announcement. Silkwave Inc., ...
10-30 18:15
Collective Mining Increases Previously Announced Bought Deal Financing to C$125 Million
Collective Mining Ltd. has increased the size of its stock offering to 6.6 million shares at C$19 each, raising C$125 million. The offering includes an option for underwriters to buy up to an additional 990,000 shares, potentially increasing total proceeds to C$144 million. The funds will support the Guayabales Project and other exploration efforts. The offering is expected to close on October 8, 2025, subject to regulatory approvals.
10-02 13:11
Chemomab Therapeutics Advances Phase 3 Plans for Nebokitug
Chemomab Therapeutics Ltd. ( ($CMMB) ) has released its Q2 earnings. Here is a ...
09-13 11:50
